Impact of Semaglutide on Tobacco Use and Related Health Behaviors
NCT06986993 on ClinicalTrials.gov · last registry update 2025-08-27
Recruiting now, toward 40 participants. Due to report 30 May 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Cigarette smoking. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 1 July 2024 — 2 years so far.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University of Oklahoma
- Sponsor type
- Other
- Enrollment
- 40
- Started
- 2024-07-01
- Primary completion
- 2028-05-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Cigarette smoking
Conditions studied
Tobacco Use
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.